Close

Form 6-K TEVA PHARMACEUTICAL INDU For: May 09

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/18/2024

1. LVS
2. TSM
3. SPY
4. NFLX
5. CSX
6. UAL
7. TSLA
8. ALK
9. EFX
10. ISRG


May 9, 2016 11:12 AM EDT
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May, 2016

Commission File Number: 001-16174

Teva Pharmaceutical Industries Ltd.
———————————————————————————————————
(Translation of registrant’s name into English)
 
Israel
———————————————————————————————————
(Jurisdiction of incorporation or organization)
 
5 Basel Street, P.O. Box 3190
Petach Tikva 4951033 Israel
———————————————————————————————————
(Address of principal executive office)
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:  [x] Form 20-F    [ ] Form 40-F
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  [ ]
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  [ ]
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:  [ ] Yes    [x] No
 
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):    n/a 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
    Teva Pharmaceutical Industries Ltd.
     
Date: 05/09/2016 By: Eyal Desheh
  Name:  Eyal Desheh
  Title: Group EVP & CFO
     
EXHIBIT INDEX

Exhibit No.   Description
 
99.1   Teva to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
     

WEBCAST ALERT – FOR IMMEDIATE RELEASE

Teva to Present at the Bank of America Merrill Lynch 2016 Health Care Conference

Jerusalem, May 9, 2016 – Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio webcast at the Bank of America Merrill Lynch 2016 Health Care Conference.
Siggi Olafsson will present on Tuesday, May 10, 2016 at 8:40 AM PT.

     
What:
  Teva Presentation at the Bank of America Merrill Lynch Healthcare Conference
Who:
  Siggi Olafsson, President and CEO, Global Generic Medicines,
Teva Pharmaceutical Industries Ltd.
When:
  Tuesday, May 10, 2016

Where: www.tevapharm.com

    How: Live over the Internet – log on to the Web at the address above and register for the event (approximately 10 minutes before). An archive of the webcast will be available on Teva’s website.  

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva’s net revenues in 2015 amounted to $19.7 billion. For more information, visit www.tevapharm.com.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings